During last week’s 22nd Annual Meeting of the Chinese Society of Clinical Oncology, held from September 18-22 in Xiamen, China, drug maker Innovent Biologics presented updated results for its proposed bevacizumab biosimilar, IBI305, in an oral session.
During last week’s 22nd Annual Meeting of the Chinese Society of Clinical Oncology, held from September 18-22 in Xiamen, China, drug maker Innovent Biologics presented updated results for its proposed bevacizumab biosimilar, IBI305, in an oral session.
IBI305, which is being investigated as a biosimilar to the reference Avastin, is being studied in the randomized, double-blind, phase 3 clinical trial CTR20160848.
In the study, patients with advanced non—small cell lung cancer were randomized to receive either the proposed biosimilar (n = 244) or the reference bevacizumab (n = 226), plus paclitaxel/carboplatin. By the cut-off date of March 31, 2019, the independent radiology review committee–assessed overall response rates were 47.1% in the biosimilar arm and 46.8% in the reference arm.
By May 22, 2019, investigator-evaluated median progression-free survival in the biosimilar arm and the reference arm were 7.3 months and 7.5 months, respectively, with no statistically significant difference (P = .893).
The biosimilar has also been studied in a randomized, double-blind, parallel, positive-controlled single-dose study, compared the pharmacokinetic profile, safety, tolerability, and immunogenicity of the biosimilar and the reference in 100 healthy volunteers. Innovent earlier said that this study met its primary end point of demonstrating similar pharmacokinetic profiles between the 2 drugs.
“We hope this drug can be launched on the market soon and provide more treatment options to patients," said Li Zhang, MD, Cancer Prevention and Treatment Center, Sun Yat-sen University, Guangzhou, Guangdong, China, in a statement announcing the results of the trial.
Hui Zhou, PhD, vice president and head of oncology strategy and medical sciences at Innovent, added that "Lung cancer is the malignant [tumor] with the highest morbidity and mortality in China. Currently, we have [8] registration trials in progress, [4] of which are for the treatment of lung cancer. We hope to bring more clinical benefits to patients through our efforts and address the significant unmet medical needs in China.”
Currently, Innovent is awaiting a regulatory decision from China’s National Medical Products Administration, which accepted for review a new drug application for the biosimilar in January of this year. The biosimilar is being evaluated under a priority review status. Also being reviewed by Chinese regulators is Innovent’s proposed biosimilar rituximab, IBI301.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.